Sensor Bio adds Dr. Michael Poku as clinical advisor
Sensor Bio said June 8, 2026, that physician executive Dr. Michael Poku has joined its advisory team as the company expands its clinical foundation. The move ties the continuous biometric platform to a value-based care leader with health system and clinical strategy experience.
Why it matters: - Dr. Michael Poku brings experience in value-based care, clinical leadership and health technology to Sensor Bio. - The hire signals Sensor Bio is pushing to make its continuous biometric infrastructure more usable inside real health systems. - Sensor Bio is positioning its open, medical-grade wearable platform for clinical programs, enterprise deployments and AI health applications.
What happened: - Sensor Bio announced June 8, 2026, that Dr. Michael Poku joined the company as a Clinical Advisor. - Dr. Poku currently serves as Chief Clinical Officer at Equality Health. - Sensor Bio described the appointment as part of its effort to expand its clinical foundation.
The details: - Dr. Poku has worked at the intersection of clinical practice and health system transformation. - He is a physician executive with expertise in value-based care, clinical leadership and health technology. - At Equality Health, Dr. Poku leads clinical strategy for one of the nation’s leading value-based care organizations. - Dr. Poku also serves as a healthcare advisor to General Atlantic. - Sensor Bio said its platform provides hardware, firmware and enterprise data infrastructure. - The company says the platform captures unfiltered physiological signals for clinical programs, AI health applications and enterprise deployments. - Sensor Bio says its technology is backed by 29 peer-reviewed studies and a decade of R&D. - The company says it is the only open, medical-grade platform built for enterprise scale. - Sensor Bio included a company website for more information.
Between the lines: - Dr. Poku’s background suggests Sensor Bio is leaning on clinical credibility as it tries to move from product promise to real-world deployment. - The company’s emphasis on open, medical-grade infrastructure points to a strategy aimed at both clinical trust and broader enterprise adoption. - Bruce Smith, Sensor Bio’s CEO, said Dr. Poku understands how to move health technology from promising to proven inside real health systems. - Dr. Poku said he is excited to support Sensor Bio as it develops clinical and commercial applications around continuous biometric data.
What's next: - Sensor Bio is expected to use Dr. Poku’s advisory role as it develops and scales clinical and commercial uses for its platform. - The company’s next phase likely centers on proving its biometric infrastructure in health system settings. - Sensor Bio may continue building out advisory and clinical relationships as it expands.
The bottom line: - Sensor Bio is adding a value-based care leader to strengthen the clinical case for its continuous biometric platform.**
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Health Industry Watch
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.